Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells.
Int J Mol Sci. 2023 Mar 14;24(6):5553. doi: 10.3390/ijms24065553.
Int J Mol Sci. 2023.
PMID: 36982651
Free PMC article.
The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines.
Bollmann LM, Skerhut AJ, Asfaha Y, Horstick N, Hanenberg H, Hamacher A, Kurz T, Kassack MU.
Bollmann LM, et al.
Int J Mol Sci. 2022 Nov 2;23(21):13398. doi: 10.3390/ijms232113398.
Int J Mol Sci. 2022.
PMID: 36362189
Free PMC article.
Item in Clipboard
5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib.
Asfaha Y, Bollmann LM, Skerhut AJ, Fischer F, Horstick N, Roth D, Wecker M, Mammen C, Smits SHJ, Fluegen G, Kassack MU, Kurz T.
Asfaha Y, et al. Among authors: bollmann lm.
Eur J Med Chem. 2024 Jan 5;263:115907. doi: 10.1016/j.ejmech.2023.115907. Epub 2023 Nov 10.
Eur J Med Chem. 2024.
PMID: 37979441
Item in Clipboard
Cite
Cite